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The fusion inhibitor T20 marks the beginning of a new era
in the management of HIV-1 disease. By inhibiting viral
entry, T20 suppress viral replication in patients carrying
strains resistant to reverse transcriptase or protease inhib-
itors. However, its antiviral activity is compromised by
mutations in gp41. Based on our previous work demon-
strating that Rapamycin (RAPA) inhibits R5 HIV-1 by
downregulating CCR5 surface expression, we now show
that RAPA and T20 synergize in antiviral activity against
R5 strains. Synergy studies using the Median Effect analy-
sis revealed that the IC50 values of RAPA and T20 in the
RAPA/T20 combination were reduced 9- and 3- fold,
respectively. Three-Dimensional modeling confirmed the
observed synergy (synergy volume of 253.85; 95 % CL :
91–147). We also show that the RAPA/T20 combo, but
not T20 alone, prevented the emergence of T20 resistance
upon continuous passage of R5 HIV-1 ADA on PBMCs for
24 weeks under subinhibitory concentrations of T20. In
addition, R5 ADA and YU-2 clones carrying T20 single
mutations 36D, 38M or 43K (4–10 fold resistance) or the
double mutation 36D/38M (65-fold resistance), were all
inhibited in the presence of RAPA. In conclusion, our
results demonstrating that the RAPA/T20 combination
has synergistic antiviral activity, prevents the emergence of
T20 resistance, and inhibits T20 resistant strains, suggest a
novel therapeutic approach to enhance the antiviral activ-
ity of T20 in patients carrying R5 strains of HIV-1.
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